Rhythm Biosciences Limited

ASX:RHY Stock Report

Market Cap: AU$32.3m

Rhythm Biosciences Management

Management criteria checks 2/4

Rhythm Biosciences' CEO is David Atkins, appointed in May 2024, has a tenure of less than a year. total yearly compensation is A$409.24K, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth A$520.00K. The average tenure of the management team and the board of directors is 1 years and 5.1 years respectively.

Key information

David Atkins

Chief executive officer

AU$409.2k

Total compensation

CEO salary percentage12.1%
CEO tenureless than a year
CEO ownership1.6%
Management average tenureless than a year
Board average tenure5.1yrs

Recent management updates

Recent updates

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

Dec 06
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Aug 09
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Apr 11
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03
Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

CEO Compensation Analysis

How has David Atkins's remuneration changed compared to Rhythm Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$409kAU$49k

-AU$7m

Compensation vs Market: David's total compensation ($USD266.09K) is about average for companies of similar size in the Australian market ($USD298.50K).

Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.


CEO

David Atkins (59 yo)

less than a year

Tenure

AU$409,243

Compensation

Dr. David Atkins, MBA, Ph. D., serves as Chief Executive Officer of Rhythm Biosciences Limited since May 13, 2024 and serves as its Managing Director and Director since September 30, 2024. He was Director...


Leadership Team

NamePositionTenureCompensationOwnership
David Atkins
CEO, MD & Directorless than a yearAU$409.24k1.61%
A$ 520.0k
Guy Carisbrooke
Financial Controller1.2yrsAU$178.96kno data
Andrea Steele
General Counsel & Joint Company Secretary2.8yrsno datano data
James Barrie
Joint Company Secretaryless than a yearno datano data

1.0yrs

Average Tenure

Experienced Management: RHY's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
David Atkins
CEO, MD & Directorless than a yearAU$409.24k1.61%
A$ 520.0k
Otto Buttula
Non-Executive Chairman5.1yrsAU$369.11k14.64%
A$ 4.7m
Louis Panaccio
Non-Executive Director7.3yrsAU$66.86k0.43%
A$ 140.3k
Susan MacLeman
Independent Deputy Chair1.8yrsAU$87.74kno data
Trevor Lockett
Non-Executive Director7.4yrsAU$227.26k0.68%
A$ 218.2k

5.1yrs

Average Tenure

60yo

Average Age

Experienced Board: RHY's board of directors are considered experienced (5.1 years average tenure).